Skip to main
IRON

IRON Stock Forecast & Price Target

IRON Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Disc Medicine Inc has demonstrated a strong positive outlook, primarily driven by the increased probability of success for bitopertin's FDA approval now set at 100%, alongside confirmed efficacy in reducing PPIX as evidenced by completed trials. Financial projections have significantly improved, with near to medium-term sales estimates for bitopertin increasing to $35 million in 2026, $190 million in 2027, $375 million in 2028, and $615 million by 2029, reflecting strong revenue potential from key hematologic indications. Additionally, the receipt of a National Priority Voucher is expected to expedite bitopertin's application review, potentially enhancing market entry timelines and boosting overall investor confidence in the company's financial performance.

Bears say

Disc Medicine Inc faces a negative outlook primarily due to several fundamental challenges impacting its development pipeline, notably relating to its lead candidate, bitopertin. Concerns have emerged regarding the clinical effectiveness of bitopertin in treating conditions such as erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), specifically regarding the potential inability to demonstrate significant treatment benefits in Phase 3 trials, as well as uncertainty around commercial viability compared to expected sales forecasts. Additionally, the company’s limited cash reserves raise concerns about its capacity to fund ongoing development and commercialization efforts, with the risk of requiring additional financing intensifying the overall uncertainty surrounding the success of its clinical programs.

IRON has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Disc Medicine Inc (IRON) Forecast

Analysts have given IRON a Buy based on their latest research and market trends.

According to 9 analysts, IRON has a Buy consensus rating as of Mar 22, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $102.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $102.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Disc Medicine Inc (IRON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.